Distinguished in Virilizing Ovarian Tumor

Dr. Janos L. Tanyi

Oncology
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
Distinguished in Virilizing Ovarian Tumor
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Janos Tanyi is an Oncologist in Philadelphia, Pennsylvania. Dr. Tanyi is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Ureteroscopy, and Bladder Reconstruction. Dr. Tanyi is currently accepting new patients.

His clinical research consists of co-authoring 89 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Medical School Of Debrecen
Residency
Semmelweis University, Medical School
Specialties
Oncology
Licenses
Obstetrics & Gynecology in PA
Board Certifications
Obstetrics And Gynecology - Gynecologic Oncology, 2014
Obstetrics And Gynecology, 2010
Fellowships
Hospital of the University of Pennsylvania
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Chester County Hospital
Pennsylvania Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Jordan Center for Gynecologic Cancers
3400 Civic Center Boulevard, West Pavilion, 3rd Floor, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Tanyi has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Vaginal Cancer
Vulvar Cancer
Cervical Cancer
Gestational Trophoblastic Disease
Ovarian Cysts
Vaginal Cysts
Ovarian Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Enrollment Status: Completed
Publish Date: February 04, 2022
Intervention Type: Procedure, Device, Drug
Study Phase: Phase 3
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: October 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Terminated
Publish Date: April 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 1
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: June 11, 2018
Intervention Type: Biological
Study Phase: Early Phase 1
View 5 Less Clinical Trials

89 Total Publications

Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report.
Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report.
Journal: Gynecologic oncology reports
Published: June 03, 2025
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Mark S. Shahin
Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Mark S. Shahin
Oncology

Alliance Cancer Specialists Doylestown

599 West State Street, Suite 312, 
Doylestown, PA 
 (25.0 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Shahin is an Oncologist in Doylestown, Pennsylvania. Dr. Shahin is rated as an Elite provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Lymphadenectomy, and Bladder Reconstruction. Dr. Shahin is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Lainie P. Martin
Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Lainie P. Martin
Oncology

Jordan Center For Gynecologic Cancers

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (0.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lainie Martin is an Oncologist in Philadelphia, Pennsylvania. Dr. Martin is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, and Virilizing Ovarian Tumor. Dr. Martin is currently accepting new patients.

Distinguished in Virilizing Ovarian Tumor
Dr. Robert L. Giuntoli
Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Robert L. Giuntoli
Oncology

Abramson Cancer Center West Chester

440 East Marshall Street, Suite 101, 
West Chester, PA 
 (21.7 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Robert Giuntoli is an Oncologist in West Chester, Pennsylvania. Dr. Giuntoli is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Cervical Cancer, Malignant Mixed Mullerian Tumor, Ovarian Carcinosarcoma, Colonoscopy, and Ureteroscopy. Dr. Giuntoli is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Tanyi's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile